MedTrace Logo

Study of FORTEO Use in Subjects in the Community Setting

NCT01078805 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4167

Last updated 2012-06-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the long-term effectiveness, safety, and tolerability of FORTEO in a larger, more diverse "real world" population than studied in clinical trials

Conditions

Interventions

DRUG

FORTEO

prescribed in accordance with usual clinical practice for up to 24 months

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01078805 on ClinicalTrials.gov